A5102311579- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Metastasis and carcinoma case studies
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- Fish Biology and Ecology Studies
- Hedgehog Signaling Pathway Studies
- Lung Cancer Diagnosis and Treatment
- Cancer and Skin Lesions
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Nonmelanoma Skin Cancer Studies
- Ferroptosis and cancer prognosis
- Colorectal Cancer Surgical Treatments
Jiangsu Cancer Hospital
2014-2025
Nanjing Medical University
2015-2024
Jiangsu Province Hospital
2021
Cancer is a disease of complex genetic alterations, and comprehensive diagnosis beneficial to match each patient appropriate therapy. However, acquisition representative tumor samples invasive sometimes impossible. Circulating DNA (ctDNA) promising tool use as non-invasive biomarker for cancer mutation profiling. Here we implemented targeted next generation sequencing (NGS) with customized gene panel 382 cancer-relevant genes on 605 ctDNA in multiple types. Overall, tumor-specific mutations...
Abstract Background Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody fused to an Fc fragment, represents potential advance because it can conveniently administered subcutaneously. Methods This open-label, single-arm, phase 2 study evaluated the efficacy and safety...
Recently, long non-coding RNAs (lncRNAs) have been shown to play important roles in human cancer biology. The purpose of this study was assess the biological role lncRNA H19 non-small-cell lung (NSCLC). Quantitative reverse transcription PCR (qRT-PCR) used detect expression tumor tissues and corresponding non-tumor NSCLC from 70 patients. higher positively correlated with advanced tumor-node-metastasis (TNM) stage size. Multivariate analyses found that could serve as an independent...
Abstract Objective To evaluate the efficacy and safety of regorafenib monotherapy or in combination with immune-checkpoint inhibitor while treating Chinese patients metastatic colorectal cancer (mCRC): a real-world study. Methods The data who received regorafenib-containing regimen as third later line treatment at ten hospitals from Aug 2017 to Jun 2020 were retrospectively analyzed, including dosing details, survival well adverse events. Survival analysis was further performed for...
191 Background: Glecirasib (JAB-21822), a highly selective, covalent and oral KRAS G12C inhibitor, has demonstrated favorable safety profile promising efficacy result as monotherapy in NSCLC. We previously reported preliminary data of glecirasib (NCT05009329) combination with cetuximab (NCT05194995) G12C-mutated advanced Colorectal Cancer (CRC); here, we present the updated results. Methods: Patients (pts) CRC harboring mutation were enrolled treated either single agent (800mg QD) or...
Cell-free DNA (cfDNA) is short, extracellular, fragmented double-stranded found in plasma. Plasma of patients with solid tumor has been to show significantly increased quantities cfDNA. Although currently poorly understood, the mechanism cfDNA generation speculated be a product genomic fragmentation during cellular apoptosis and necrosis. Sequencing origin identified biomarkers, elucidating molecular pathology assisting accurate diagnosis. In this study, we performed whole-genome sequencing...
Currently, in clinical settings, all TP53 mutations have been considered equally. However, numerous studies demonstrated that the position and type of mutation differential effects on prognosis. Such discrepancy can be partially due to lack unifying classification system for mutations. In present study, two most frequently used systems were compared, according location or its functional p53 protein impact overall survival (OS) time 379 Chinese patients with advanced lung cancer was analyzed....
Tumor mutation burden (TMB) has an important association with immunotherapy responses. TMB in the Chinese population not been well established. Finding differences between and Caucasian populations elucidating underlying biological mechanisms of high might help develop more precise effective means for response prediction.Chinese cancer patients fresh tissue (n=2,177), formalin-fixed, paraffin-embed (FFPE) specimens (n=3,294), pleural fluid (n=189) were profiled using a 295- or 520-gene...
Nimotuzumab is shown to be efficacious in advanced pancreatic cancer treatment, but its predictive marker has not been established.To investigate the impact of EGFR and KRAS status on antitumor efficacy nimotuzumab explore underlying mechanism.EGFR expressions cell lines, BxPC3, Panc-1, Patu-8988, were analyzed by Western blot immunocytochemistry, was determined gene sequencing. Anti-tumor effect evaluated vitro vivo. The related molecules pathway IL-6 blot, immunohistochemistry, and/or...
Fruquintinib is approved in China for patients with metastatic colorectal cancer (CRC) who progressed after 2 lines of chemotherapy. This postmarketing study was conducted to evaluate the safety fruquintinib Chinese population, including previously treated advanced CRC and other solid tumors.
This study aims to explain the role and mechanism of lncRNA LINC00152 in esophageal cancer.The 30 pairs cancer adjacent normal tissues were collected measuring expression by ISH RT-qPCR assay. In next cell experiment, Eca 109 Kyse 150 cells divided into 3 groups: NC group treated with non-treatment; BL transfected empty vector LINC00152. The proliferation measured MTT assay; apoptosis cycle evaluated flow cytometry. relative proteins expressions WB assay.Compared groups, rate groups...
Aim was to explore the association of ERCC1 and TS mRNA levels with disease free survival (DFS) in Chinese colorectal cancer (CRC) patients receiving oxaliplatin 5-FU based adjuvant chemotherapy. Total 112 stage II-III CRC were respectively treated by four different chemotherapy regimens after curative operation. The primary tumor measured real-time RT-PCR. Kaplan–Meier curves log-rank tests used for DFS analysis. Cox proportional hazards model prognostic In univariate analysis, hazard ratio...
Gastrointestinal tract cancers have high incidence and mortality in China, but their molecular characteristics not been fully investigated. We sequenced 432 tumor samples from the colorectum, stomach, pancreas, gallbladder, biliary to investigate cancer-related mutations detail landscape of microsatellite instability (MSI), mutation burden (TMB), chromosomal (CIN). observed highest TMB colorectal gastric lowest gastrointestinal stromal tumors (GISTs). Twenty-four hyper-mutated were...
Bevacizumab has an important and evolving role in improving outcomes patients with metastatic colorectal cancer (mCRC) worldwide was approved China 2010. However, there are limited real-world data on the efficacy safety of chemotherapy regimens combined bevacizumab Chinese mCRC. This observational, phase IV trial study aimed to obtain more experience mCRC patients.Between September 2013 November 2016, histologically confirmed were enrolled a prospective, multicenter, non-interventional at 26...
It was recently demonstrated that long noncoding RNAs (lncRNAs) have key regulation functions in the biology of human cancer. The current study aimed to determine expression, clinicopathological characteristics and functional roles lncRNA PCAT18 gastric cancer (GC). By analysis (Gene Expression Omnibus) GEO TCGA data, following experimental verification, we identified function role molecular mechanism tumorigenesis GC. We discovered is significantly decreased paired GC tissues correlates...
Aim: This study was to evaluate whether CO2CP level in venous blood could predict prognosis of patients with colorectal cancer (CRC). Materials & methods: A retrospective cohort 238 CRC who received surgical resection and 176 Stage IV were included. total 114 healthy people recruited as control. levels obtained from medical records. Survival analysis performed predictive potential. The divided into high or low group based on optimal cut-off values. Conclusion: decreased associated advanced...
3021 Background: KN035 is a novel fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc formulated for subcutaneous injection. This open-label phase II study evaluated the safety antitumor activity in patients with advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) cancer. Methods: The included aged ≥18 years previously treated MSI-H/dMMR colorectal cancer (CRC) or other solid tumors. status was assessed centrally CRC gastric (GC)...
Background. Oxaliplatin-induced peripheral neuropathy (OIPN) is one of the most common side effects oxaliplatin, which can cause reduction and cessation oxaliplatin-based chemotherapy significantly affect patients’ quality life. However, no drug has got recognition to prevent or treat OIPN. Yiqi-Wenjing-Fang (YWF) a joint name Chinese medicine prescriptions with similar tonifying qi warming meridians, represented by Huangqi Guizhi Wuwu decoction (HGWD) Danggui Sini (DSD), both from “Treatise...
e15547 Background: Preclinical and clinical data have demonstrated the synergistic anti-tumor effects of surufatinib, a novel VEGFR1-3, FGFR CSF-1R inhibitor, in combination with immune checkpoint inhibitors (ICIs)/chemotherapy. A phase Ib/II, open-label study (NCT04929652) was conducted to evaluate efficacy safety surufatinib plus camrelizumab (anti-PD-1), irinotecan GM-CSF as second-line treatment advanced colorectal cancer (CRC). In Ib part, this showed favorable profile, which presented...
3574 Background: First-line fluoropyrimidine (FL), oxaliplatin (OX), irinotecan (IRI) plus BEV had better efficacy but worse safety vs FL, IRI for mCRC. Preliminary data showed promising anti-tumor activity and acceptable toxicity of alternating FL OX IRI. This study aimed to assess the schedule modified capecitabine (XEL), (i.e., mXELOX) XEL, mXELIRI) Methods: single-arm phase II trial was conducted in China. Patients aged 18–75 years, with histologically confirmed unresectable mCRC, ≥one...
e16304 Background: Advanced gastrointestinal (GI) tumors, such as colorectal, gastric and pancreatic cancers (CRC, GC, PC), esophageal squamous cell carcinoma (ESCC), 20%-50% with liver metastases (LMs) have a poor prognosis. Previous trials showed that anlotinib plus chemotherapy has promising clinical activity tolerable safety profile for advanced CRC ESCC, especially LMs. In this phase II trial, we assessed the efficacy of first-line treatment LMs GI tumors. Methods: Patients unresectable...
Objectives Clinical studies have shown that bevacizumab plus chemotherapy significantly improves efficacy in metastatic colorectal cancer (mCRC). This prospective study aims to investigate the and safety of changing second-line treatment raltitrexed-based regimens mCRC patients who failed first-line fluorouracil-based regimen with or without bevacizumab/cetuximab. Methods is a prospective, open-label, multicenter, phase II clinical study. A total 100 after failure bevacizumab/cetuximab were...